$COCH
Envoy Medical, Inc. Stock $coch

$coch Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000121390024067381 Filed on August 12, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$56.00K	$68.00K	$0.00
YoY Change	-30.0%
Cost Of Revenue	$187.0K	$245.0K	$162.0K
YoY Change	-1.06%	51.23%
Gross Profit	-$131.0K	-$177.0K	-$162.0K
YoY Change	20.18%	9.26%
Gross Profit Margin	-233.93%	-260.29%
Selling, General & Admin	$2.086M	$2.092M	$2.228M
YoY Change	46.28%	-6.1%
% of Gross Profit
Research & Development	$2.757M	$2.591M	$2.153M
YoY Change	49.03%	20.34%
% of Gross Profit
Depreciation & Amortization	$49.00K	$42.00K
YoY Change	-42.35%
% of Gross Profit
Operating Expenses	$4.843M	$4.683M	$98.60K
YoY Change	47.83%	4649.49%	-89.06%
Operating Profit	-$4.974M	-$4.860M	-$98.60K
YoY Change	46.94%	4829.21%	-89.06%
Interest Expense	-$690.0K	$669.0K	$383.5K
YoY Change		74.43%	-90.48%
% of Operating Profit
Other Income/Expense, Net	-$986.0K	$913.0K	-$1.302M
YoY Change	-119.93%	-170.13%	-1950.65%
Pretax Income	-$5.960M	-$3.947M	-$1.017M
YoY Change	-481.32%	288.1%	-131.79%
Income Tax			$121.2K
% Of Pretax Income
Net Earnings	-$5.960M	-$3.947M	-$1.138M
YoY Change	-481.32%	246.76%	-136.83%
Net Earnings / Revenue	-10642.86%	-5804.41%
Basic Earnings Per Share	-$0.37	-$0.27	-$1.31
Diluted Earnings Per Share	-$0.37	-$0.27	-$0.08
COMMON SHARES
Basic Shares Outstanding	19.60M shares	19.60M shares	10.12M shares
Diluted Shares Outstanding	19.62M shares	19.60M shares	10.12M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.424M	$1.746M	$132.8K
YoY Change	-40.54%	1215.06%	-72.16%
Cash & Equivalents	$4.424M	$1.746M	$132.8K
Short-Term Investments
Other Short-Term Assets	$842.0K	$1.466M	$264.9K
YoY Change	-91.9%	453.37%	-42.87%
Inventory	$1.641M	$1.582M
Prepaid Expenses			$264.9K
Receivables	$197.0K	$174.0K
Other Receivables	$32.00K	$28.00K
Total Short-Term Assets	$7.136M	$4.996M	$397.7K
YoY Change	-68.6%	1156.23%	-57.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.197M	$632.0K
YoY Change	216.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$44.65M
YoY Change			-89.51%
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$2.261M	$1.741M	$44.65M
YoY Change	159.29%	-96.1%	-89.53%
TOTAL ASSETS
Total Short-Term Assets	$7.136M	$4.996M	$397.7K
Total Long-Term Assets	$2.261M	$1.741M	$44.65M
Total Assets	$9.397M	$6.737M	$45.04M
YoY Change	-60.18%	-85.04%	-89.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.757M	$1.589M	$1.432M
YoY Change	-48.03%	11.0%	61.83%
Accrued Expenses	$6.854M	$6.004M	$5.124M
YoY Change	69.15%	17.18%	85.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$2.690M
YoY Change		-100.0%	79.33%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.074M	$8.058M	$9.347M
YoY Change	-33.29%	-13.79%	77.9%
LONG-TERM LIABILITIES
Long-Term Debt	$14.36M	$7.292M	$0.00
YoY Change
Other Long-Term Liabilities	$4.496M	$3.774M	$11.89M
YoY Change	20.25%	-68.26%	-34.22%
Total Long-Term Liabilities	$18.85M	$11.07M	$11.89M
YoY Change	404.2%	-6.93%	-34.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.074M	$8.058M	$9.347M
Total Long-Term Liabilities	$18.85M	$11.07M	$11.89M
Total Liabilities	$27.93M	$19.12M	$21.24M
YoY Change	61.03%	-9.95%	-8.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$277.5M	-$270.2M	-$20.79M
YoY Change	10.55%	1199.57%	-3.09%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$18.53M	-$12.39M	-$20.79M
YoY Change
Total Liabilities & Shareholders Equity	$9.397M	$6.737M	$45.04M
YoY Change	-60.18%	-85.04%	-89.46%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$5.960M	-$3.947M	-$1.138M
YoY Change	-481.32%	246.76%	-136.83%
Depreciation, Depletion And Amortization	$49.00K	$42.00K
YoY Change	-42.35%
Cash From Operating Activities	-$2.807M	-$4.908M	-$678.9K
YoY Change	-9.04%	622.89%	69.67%
INVESTING ACTIVITIES
Capital Expenditures	$1.157M	$357.0K
YoY Change	776.52%
Acquisitions
YoY Change
Other Investing Activities		-$433.0K	$252.0K
YoY Change		-271.83%
Cash From Investing Activities	-$615.0K	-$790.0K	$252.0K
YoY Change	-99.84%	-413.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.101M	2.500M	455.7K
YoY Change	-98.51%	448.62%	-39.24%
NET CHANGE
Cash From Operating Activities	-2.807M	-4.908M	-678.9K
Cash From Investing Activities	-615.0K	-790.0K	252.0K
Cash From Financing Activities	6.101M	2.500M	455.7K
Net Change In Cash	2.679M	-3.198M	28.75K
YoY Change	-83.9%	-11223.48%	-91.78%
FREE CASH FLOW
Cash From Operating Activities	-$2.807M	-$4.908M	-$678.9K
Capital Expenditures	$1.157M	$357.0K
Free Cash Flow	-$3.964M	-$5.265M
YoY Change	23.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40133
	dei	Entity Registrant Name EntityRegistrantName	ENVOY MEDICAL, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-1369123
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4875 White Bear Parkway
	dei	Entity Address City Or Town EntityAddressCityOrTown	White Bear Lake
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55110
	dei	City Area Code CityAreaCode	(877)
	dei	Local Phone Number LocalPhoneNumber	900-3277
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19599982	shares
CY2024Q2	us-gaap	Cash Cash	1746000	usd
CY2023Q4	us-gaap	Cash Cash	4218000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	174000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	70000	usd
CY2024Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	28000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	176000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1582000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1404000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1466000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	957000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	4996000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	6825000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	632000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	351000	usd
CY2024Q2	us-gaap	Assets Assets	6737000	usd
CY2023Q4	us-gaap	Assets Assets	7640000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1589000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1554000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6004000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4613000	usd
CY2024Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	290000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	311000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8058000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6636000	usd
CY2024Q2	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	1923000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	1923000	usd
CY2024Q2	coch	Publicly Traded Warrant Liability Noncurrent PubliclyTradedWarrantLiabilityNoncurrent	708000	usd
CY2023Q4	coch	Publicly Traded Warrant Liability Noncurrent PubliclyTradedWarrantLiabilityNoncurrent	332000	usd
CY2023Q4	coch	Forward Purchase Agreement Put Option Liability Noncurrent ForwardPurchaseAgreementPutOptionLiabilityNoncurrent	103000	usd
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	22000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	4000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	19124000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	9402000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	257920000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	255596000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270189000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-257242000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-120000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-118000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-12387000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1762000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6737000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7640000	usd
CY2024Q2	us-gaap	Revenues Revenues	68000	usd
CY2023Q2	us-gaap	Revenues Revenues	63000	usd
	us-gaap	Revenues Revenues	127000	usd
	us-gaap	Revenues Revenues	141000	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	245000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	162000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	398000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	337000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2591000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2153000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4951000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4080000	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	497000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	383000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	822000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	754000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1595000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1845000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3714000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3221000	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	4928000	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	4543000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	9885000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	8392000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4860000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4480000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9758000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8251000	usd
CY2023Q2	coch	Change In Fair Value Of Convertible Notes Payablerelated Party ChangeInFairValueOfConvertibleNotesPayablerelatedParty	8766000	usd
	coch	Change In Fair Value Of Convertible Notes Payablerelated Party ChangeInFairValueOfConvertibleNotesPayablerelatedParty	18143000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	103000	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-244000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	18000	usd
CY2024Q2	coch	Change In Fair Value Of Publicly Traded Warrant Liability ChangeInFairValueOfPubliclyTradedWarrantLiability	-801000	usd
	coch	Change In Fair Value Of Publicly Traded Warrant Liability ChangeInFairValueOfPubliclyTradedWarrantLiability	376000	usd
CY2024Q2	us-gaap	Interest Expense Other InterestExpenseOther	132000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	168000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-105000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	913000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8766000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-459000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18248000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-3947000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-13246000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10217000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-26499000	usd
CY2024Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1365000	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	2730000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5312000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13246000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12947000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26499000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.62
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19599982	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10122581	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19599982	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10122581	shares
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3948000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13247000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10219000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26499000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1762000	usd
CY2024Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1365000	usd
CY2024Q1	coch	Adjustments To Additional Paid In Capital Sale Of Common Stock Associated With Forward Purchase Agreement AdjustmentsToAdditionalPaidInCapitalSaleOfCommonStockAssociatedWithForwardPurchaseAgreement	1683000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	123000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	179000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6270000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-7413000	usd
CY2024Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1365000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	142000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	197000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-3947000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-12387000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-36195000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	1952000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	1000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13253000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-47495000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	15714000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-13246000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-45028000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10217000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-26499000	usd
	us-gaap	Depreciation Depreciation	76000	usd
	us-gaap	Depreciation Depreciation	56000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	265000	usd
	coch	Change In Fair Value Of Convertible Notes Payablerelated Party ChangeInFairValueOfConvertibleNotesPayablerelatedParty	18143000	usd
	coch	Other Expense Related To Warrant Liabilityrelated Party OtherExpenseRelatedToWarrantLiabilityrelatedParty	-104000	usd
	coch	Change In Fair Value Of Publicly Traded Warrant Liability ChangeInFairValueOfPubliclyTradedWarrantLiability	376000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	18000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	103000	usd
	coch	Change In Operating Lease Rightofuse Assetsrelated Party ChangeInOperatingLeaseRightofuseAssetsrelatedParty	-645000	usd
	coch	Change In Operating Lease Rightofuse Assetsrelated Party ChangeInOperatingLeaseRightofuseAssetsrelatedParty	52000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	262000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	-17000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	104000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-148000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	440000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-6000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-33000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	165000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	35000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1357000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	734000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-75000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1171000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	139000	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-21000	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-132000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10754000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7045000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	357000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70000	usd
	us-gaap	Payments For Other Deposits PaymentsForOtherDeposits	542000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-899000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	7000000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	7500000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1683000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9183000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7000000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2472000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-115000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4218000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	183000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1746000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68000	usd
	coch	Deemed Capital Contribution From Related Party DeemedCapitalContributionFromRelatedParty	2988000	usd
	coch	Dividends On Series A Preferred Shares DividendsOnSeriesAPreferredShares	2730000	usd
	us-gaap	Stock Issued1 StockIssued1	376000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. Nature of the Business and Basis of Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Envoy Medical, Inc. (“Envoy Medical” or the “Company”) is a hearing health company focused on providing innovative medical technologies across the hearing loss spectrum. Envoy Medical’s technologies are designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they desire. The Company’s first commercial product, the Esteem® Fully Implanted Active Middle Ear Implant (“Esteem FI-AMEI”), is a fully implanted active middle ear hearing device. The Esteem FI-AMEI was approved for sale in 2010 by the United States Food and Drug Administration (“FDA”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Envoy Medical believes the fully implanted Acclaim® Cochlear Implant (“Acclaim CI”) is a first-of-its-kind cochlear implant. Envoy Medical’s fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound. The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI will only be indicated for adults who have been deemed adequate candidates by a qualified physician. The Acclaim CI received the Breakthrough Device Designation from the FDA in 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 29, 2023 (the “Closing Date”), a merger transaction between Envoy Medical Corporation, Anzu Special Acquisition Corp I (“Anzu”) and Envoy Merger Sub, Inc., a directly, wholly owned subsidiary of Anzu (“Merger Sub”) was completed (hereinafter, the “Merger” or “Business Combination”, see Note 3) pursuant to the business combination agreement, dated as of April 17, 2023 (as amended, the “Business Combination Agreement”). In connection with the closing of the Merger (the “Closing”), Merger Sub merged with Envoy Medical Corporation, with Envoy Medical Corporation surviving the merger as a wholly owned subsidiary of Anzu. In connection with the Closing, Anzu changed its name to Envoy Medical, Inc. The Company’s Class A common stock, par value $0.0001 per share (“Common Stock”), and the Company’s warrants commenced trading on the Nasdaq Stock Market LLC (“Nasdaq”) on October 2, 2023 under the symbols “COCH” and “COCHW,” respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 17, 2023, prior to entering into the Business Combination Agreement, Anzu and Envoy Medical Corporation entered into an agreement (as amended to date, the “Forward Purchase Agreement”) with Meteora Special Opportunity Fund I, LP (“MSOF”), Meteora Capital Partners, LP (“MCP”), Meteora Select Trading Opportunities Master, LP (“MSTO”) and Meteora Strategic Capital, LLC (“MSC” and, collectively with MSOF, MCP and MSTO, the “Sellers” or “Meteora parties”) for an over-the-counter equity prepaid forward transaction.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the Forward Purchase Agreement, on the Closing Date, the Sellers purchased 425,606 shares of the Company’s Common Stock (the “Recycled Shares”) directly from the redeeming stockholders of Anzu. Also, effective upon on the Closing Date, the Company paid to the Sellers a prepayment amount of $4.5 million required under the Forward Purchase Agreement directly from the trust account and transferred to the Sellers 8,512 shares of Common Stock (the “Share Consideration”). During the three months ended March 31, 2024, the Sellers sold the full amount of the Recycled Shares, and, pursuant to the Forward Purchase Agreement, the Company received $4.00 per share sold, or approximately $1.7 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, pursuant to the subscription agreement, dated April 17, 2023 (as amended to date, the “Subscription Agreement”), by and between Anzu and Anzu SPAC GP I LLC (the “Sponsor”), the Company issued, and certain affiliates of the Sponsor purchased, concurrently with the Closing, an aggregate of 1,000,000 shares of the Company’s Series A preferred stock, par value $0.0001 per share (“Series A Preferred Stock”) in a private placement (the “PIPE Transaction”) at a price of $10.00 per share for an aggregate purchase price of $10.0 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the convertible promissory note, dated April 17, 2023, between Envoy Medical Corporation and GAT Funding, LLC (as amended to date, the “Envoy Bridge Note”), the Company issued 1,000,000 shares of the Company’s Series A Preferred Stock to GAT Funding, LLC in exchange for the conversion of the Envoy Bridge Note in full, concurrently with the Closing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The unaudited condensed consolidated financials include the accounts of Envoy Medical and its wholly-owned subsidiaries Envoy Medical Corporation and Envoy Medical GmbH (Ansbach) (GmbH), which operates a sales office in Germany. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Unaudited financial information</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that might be expected for the full year. As such, the information included in this report should be read in conjunction with the Company’s audited financial statements as of and for the year ended December 31, 2023, which are included in the Company’s Form 10-K, dated and filed with the SEC on April 1, 2024, which is accessible on the SEC’s website at www.sec.gov. The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited consolidated financial statements of the Company, but does not include all the disclosures required by U.S. GAAP.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended June 30, 2024, there were no changes to the Company’s significant accounting policies as described in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2023.</p>
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	425606	shares
	us-gaap	Prepayment Fees On Advances Net PrepaymentFeesOnAdvancesNet	4500000	usd
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	8512	shares
CY2024Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	4
	coch	Proceeds From Purchase Agreement Amount ProceedsFromPurchaseAgreementAmount	1700000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270200000	usd
CY2024Q1	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	5000000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2500000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Other Receivables ProceedsFromSaleOfOtherReceivables	1700000	usd
CY2023Q3	us-gaap	Proceeds From Previous Acquisition ProceedsFromPreviousAcquisition	11700000	usd
CY2024Q2	us-gaap	Cash Cash	1700000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to the useful lives of property and equipment, inventory reserves, warranty liability, stock-based compensation expense, the fair value of the forward purchase agreement put option liability, the fair value of the forward purchase agreement warrant liability and the outcome of litigation. Estimates and assumptions are reviewed periodically and the effect of changes, if any, are reflected in the unaudited condensed consolidated statements of operations and comprehensive loss.</p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Reclassification</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain items in prior financial statements have been reclassified to conform to the current presentation.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Concentration of Credit Risk and Significant Customers</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and accounts receivable, net. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to accounts receivable, the Company performs credit evaluations of its customers and does not require collateral. There have been no material losses on the Company’s accounts receivable. There were no customers that accounted for 10.0% or more of sales for the three and six months ended June 30, 2024 and 2023, respectively. There were no customers that accounted for 10.0% or more of the accounts receivable balance as of June 30, 2024 and December 31, 2023, respectively.</p>
CY2024Q2	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	2200000	usd
CY2024Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2200000	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	300000	usd
	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5300000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13200000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12900000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26500000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
	us-gaap	Payments For Purchase Of Other Assets1 PaymentsForPurchaseOfOtherAssets1	10000000	usd
	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.12	pure
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	1390000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1162000	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	108000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	158000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	84000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	84000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1582000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1404000	usd
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2030-12-31
CY2024Q2	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	1664	sqft
CY2024Q2	us-gaap	Area Of Land AreaOfLand	11540	sqft
	us-gaap	Lease Cost LeaseCost	150000000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	50000000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	208000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	68000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	118000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	111000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	92000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	229000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	223000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	230000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	195000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	349000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1318000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	22000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1296000	usd
CY2023Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2234000	usd
	coch	Standard Product Warranty Utilization StandardProductWarrantyUtilization	-21000	usd
CY2024Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2213000	usd
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P5Y
CY2024Q2	us-gaap	Percentage Of Weighted Average Cost Inventory PercentageOfWeightedAverageCostInventory	0.037	pure
CY2024Q2	us-gaap	Product Liability Contingency Accrual Discount Rate ProductLiabilityContingencyAccrualDiscountRate	0.051	pure
	coch	Withdrawal Of Funds WithdrawalOfFunds	5000000	usd
CY2024Q2	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	2500000	usd
	us-gaap	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable	2027-02-27
CY2024Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	250000	shares
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	197000	usd
CY2024Q2	us-gaap	Interest Expense Other InterestExpenseOther	132000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	168000	usd
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	500000	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	250000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	100000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	11.5
CY2024Q2	us-gaap	Auction Market Preferred Securities Stock Series Par Value Per Share AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare	15
	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.12	pure
CY2024Q2	us-gaap	Other Additional Capital OtherAdditionalCapital	10000000	usd
CY2024Q2	coch	Unpaid Dividend UnpaidDividend	2900000	usd
CY2023Q4	coch	Unpaid Dividend UnpaidDividend	800000	usd
	us-gaap	Preferred Stock Dividends Per Share Cash Paid PreferredStockDividendsPerShareCashPaid	10
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1967734	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.38
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y9M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	114505	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	30000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.35
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2052239	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.36
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M18D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	87501000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	962082	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.4
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y3M18D
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1300000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	562000	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	50000	usd
CY2023	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	50000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-3947000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-13246000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10217000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-26499000	usd
CY2024Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1365000	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	2730000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5312000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13246000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12947000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26499000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19599982	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10122581	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19599982	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10122581	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.62
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24756342	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	263000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24756342	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	263000	shares
CY2024Q2	us-gaap	Loans Payable LoansPayable	2500000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	3874394	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2023Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-12947000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13246000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-26499000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5312000	usd
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.62
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10122581	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10122581	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19599982	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19599982	shares
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax		usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	coch	Change In Fair Value Of Convertible Notes Payablerelated Party ChangeInFairValueOfConvertibleNotesPayablerelatedParty		usd
	coch	Other Expense Related To Warrant Liabilityrelated Party OtherExpenseRelatedToWarrantLiabilityrelatedParty		usd
	coch	Change In Fair Value Of Publicly Traded Warrant Liability ChangeInFairValueOfPubliclyTradedWarrantLiability		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables		usd
	us-gaap	Payments For Other Deposits PaymentsForOtherDeposits		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	coch	Deemed Capital Contribution From Related Party DeemedCapitalContributionFromRelatedParty		usd
	coch	Dividends On Series A Preferred Shares DividendsOnSeriesAPreferredShares		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
	coch	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
	coch	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue		usd
	coch	Sharebased Compensation Arrangement By Sharebased Payment Award Options Terminated Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerminatedWeightedAverageRemainingContractualTerm
	coch	Share Based Compensation Arrangement By Share Based Payment Award Options Terminated Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTerminatedIntrinsicValue		usd
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10122581	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10122581	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19599982	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19599982	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.62
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001840877

Files In Submission

Name	View Source	Status
0001213900-24-067381-index-headers.html	Edgar Link	pending
0001213900-24-067381-index.html	Edgar Link	pending
0001213900-24-067381.txt	Edgar Link	pending
0001213900-24-067381-xbrl.zip	Edgar Link	pending
coch-20240630.xsd	Edgar Link	pending
ea0211069-10q_envoy.htm	Edgar Link	pending
ea021106901ex10-1_envoy.htm	Edgar Link	pending
ea021106901ex31-1_envoy.htm	Edgar Link	pending
ea021106901ex31-2_envoy.htm	Edgar Link	pending
ea021106901ex32-1_envoy.htm	Edgar Link	pending
ea021106901ex32-2_envoy.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
coch-20240630_def.xml	Edgar Link	unprocessable
coch-20240630_lab.xml	Edgar Link	unprocessable
coch-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0211069-10q_envoy_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
coch-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$COCH
Envoy Medical, Inc. Stock $coch

2024 Q3 Form 10-Q Financial Statement

#000121390024067381 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COCH Envoy Medical, Inc. Stock $coch

2024 Q3 Form 10-Q Financial Statement

#000121390024067381 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COCH
Envoy Medical, Inc. Stock $coch